AtaiBeckley Inc. Insider Trading

ATAI

Last 12 months

Insiders sold $1.66M and bought nothing on the open market.

91% of the selling was scheduled in advance under 10b5-1 plans. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$1.66M

0 buys · 6 sales

Under a 10b5-1 plan

91%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

None

in the last two years

Get an email when ATAI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 7	Robert Hershberg Director	Sold10b5-1 plan	100,000	$4.96	496K	50%	Form 4
Jun 26	Gerd Kochendoerfer Chief Operating Officer	Sold10b5-1 plan	50,000	$5.00	250K	100%	Form 4
Jun 25	Kevin James Craig Chief Medical Officer	Sold10b5-1 plan	42,579	$4.51	192K	83%	Form 4
Apr 20	Kevin James Craig Chief Medical Officer	Sold10b5-1 plan	42,579	$5.00	213K	83%	Form 4
Mar 20	Kevin James Craig Chief Medical Officer	Sold10b5-1 plan	100,000	$3.55	355K	92%	Form 4
Jan 2	Cosmo Feilding-Mellen Director	SoldNo plan	39,594	$3.90	154K	0.5%	Form 4

Jul 710b5-1 plan
Robert Hershberg
Director · sold 100,000 at $4.96
496K
50% of stake
Jun 2610b5-1 plan
Gerd Kochendoerfer
Chief Operating Officer · sold 50,000 at $5.00
250K
100% of stake
Jun 2510b5-1 plan
Kevin James Craig
Chief Medical Officer · sold 42,579 at $4.51
192K
83% of stake
Apr 2010b5-1 plan
Kevin James Craig
Chief Medical Officer · sold 42,579 at $5.00
213K
83% of stake
Mar 2010b5-1 plan
Kevin James Craig
Chief Medical Officer · sold 100,000 at $3.55
355K
92% of stake
Jan 2No plan
Cosmo Feilding-Mellen
Director · sold 39,594 at $3.90
154K
0.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ATAI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ATAI

CompareIntrinsic value

PRPHProPhase Labs Inc.

$0.01-42.00%0

CPHIChina Pharma Holdings Inc.

$0.59-3.28%15

MRKRMarker Therapeutics, Inc.

$1.01+3.06%25

CAMPCamp4 Therapeutics Corp.

$3.74-2.35%40

ENSCEnsysce Biosciences Inc.

$0.37-2.20%40

TXMDTherapeuticsMD, Inc.

$1.82+2.25%25

CLSDQClearside Biomedical, Inc.

No recent price10

UPBUpstream Bio, Inc.

$3.70+9.14%21

Held by ETFs

ATAI is in 19 US ETFs. The largest of them, with ATAI's weight in each:

Spot a number that looks wrong? Check it in ATAI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ATAI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.